Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial - PubMed
4 hours ago
- #biomarkers
- #colorectal cancer
- #ramucirumab
- Study evaluated plasma biomarkers in RAS wild-type metastatic colorectal cancer patients undergoing second-line FOLFIRI plus ramucirumab after anti-EGFR therapy.
- RAS mutations detected in ctDNA at baseline in 44% of patients were linked to shorter overall survival (14.8 vs. 28.1 months) and lower objective response rates.
- Elevated baseline interleukin-8 (IL-8) levels were associated with poorer overall survival (16.5 vs. 32.2 months), with higher IL-8 found in patients having RAS mutations.
- Findings suggest RAS mutations in ctDNA and high IL-8 are prognostic markers for worse outcomes and indicate a potential molecular-inflammatory interplay affecting VEGFR2 blockade resistance.